畅肺防喘方对哮喘大鼠气道重构和炎症介质的影响的试验研究
|
摘要
目的畅肺防喘方是课题组多年来治疗哮喘的经验方,应用于临床疗效显著,该方能有效缓解患者支气管痉挛,提高患者生活质量。其免疫作用已有初步探索。本课题拟在前期临床观察和实验研究的基础上,进一步从分子生物学和免疫学水平,研究畅肺防喘方防治哮喘的作用机制。本课题通过体外实验,运用血清药理学方法,研究该方对支气管平滑肌细胞的抑制增殖作用;并通过体内实验,观察该方对哮喘模型大鼠的平喘作用和对其支气管、肺组织形态学的影响,研究其血液、肺泡灌洗液中EOS(嗜酸性粒细胞)、IgE及相关趋化因子Eotaxin(嗜酸性粒细胞趋化蛋白)、ICAM-1(细胞间粘附分子-1)表达水平的变化。进一步从细胞和分子生物学水平探讨畅肺防喘方治疗哮喘的作用机理,从而为开发临床防治哮喘的有效中药制剂奠定基础。
方法1、体内实验方法:取大鼠支气管肺泡灌洗液(BALF)进行细胞计数和分类,对其上清液以双抗夹心酶联免疫吸附(ELISA)法进行细胞因子Eotaxin、ICAM-1含量的测定;血细胞计数分类,放免法检测血中IgE含量;制备大鼠支气管及肺组织切片,HE染色,观察气道重构情况;免疫组化法检测肺及支气管局部组织Eotaxin、ICAM-1的表达。2、体外实验方法:含药血清制备;MTT酶标法、免疫细胞化学(ICC)法测支气管平滑肌细胞的增殖水平,以了解该方对抗哮喘气道重构的作用。
结果1、体内试验:1.1实验结果显示畅肺防喘方可显著降低WBC数量,尤其是嗜酸性细胞(P<0.01),说明该方可明显改善呼吸道炎性症状。实验结果还表明血清IgE的含量降低,说明其治疗和预防作用可能是通过此途径来实现的,为畅肺防喘方治疗支气管哮喘的临床应用提供了有力的实验依据。
1.2 ELISA法结果显示:与正常组比较模型组支气管肺泡灌洗液中Eotaxin、ICAM-1均显著升高,经治疗后,上述指标均显著降低。说明畅肺防喘方可显著抑制哮喘大鼠Eotaxin、ICAM-1表达。前期研究表明,该方对EOS的抑制作用较为明显。EOS浸润是哮喘炎症的显著病理生理特征,EOS向炎症部位趋化、募集,是哮喘病症中重要的病理过程,其过程机制与Eotaxin、ICAM-1等关系密切。结果提示,对Eotaxin、ICAM-1的抑制作用可能是畅肺防喘方治疗哮喘的作用机制之一。
1.3肺组织病理切片HE染色显示,抗原激发后模型组肺组织嗜酸性粒细胞和炎症细胞浸润与对照组相比有明显增多(P<0.01)。
2、体外实验:本实验发现畅肺防喘方高、中、小剂量组含药血清对支气管平滑肌增殖细胞核抗原(PCNA)表达的平均光密度明显高于对照组(P<0.05),与地塞米松组无显著性差异(P>0.05),它与MTT法观察结果一致。本次实验证明,与对照组比较,畅肺防喘方高、中剂量含药血清组能明显抑制大鼠支气管平滑肌细胞(ASMC)的增殖,与地塞米松含药血清组比较无显著性差异,而畅肺防喘方小剂量含药血清组则无明显作用,考虑可能与药物浓度有关。且随着作用时间的延长,含药血清对支气管平滑肌细胞的抑制作用有增强趋势。说明畅肺防喘方可能通过抑制组胺(His)促ASMC增殖作用而达到防治哮喘的效果,且存在一定的剂量、时间依赖关系。
结论1、体内实验:证实了畅肺防喘方的平喘作用(症状改善,血中IgE、EOS,BALF中EOS含量下降,支气管及肺形态学的变化)和作用机制(抑制趋化因子Eotaxin和粘附分子ICAM-1的表达)。
2、体外实验:运用血清药理学方法证实了畅肺防喘方有较好的抗哮喘大鼠气道重构的作用(抑制支气管平滑肌细胞增殖)和抑制平滑肌细胞的PCNA的作用。
3、明确了宣肺平喘、清热化痰法对哮喘的防治作用机制。
4、为进一步开发具有较好疗效的中药复方制剂,提供了实验依据。
objective
The Prescription of Patecy Lung and preventing asthma,which is used in clinical medicine is preliminary exploration in immunization for many years,and effect was Significantly. Inhibition of value-added for smooth muscle cell of bronchus were studied though Serum pharmacology method in-vitro method assay; Thought in-vivo experiment,the affect of preventing asthma and lung morphology to the model asthma pig mouse which were medicated by this Prescription were observed.The diversification of EOS、IgE、Eotaxin of correlation factor and expression level changes of adhesion molecule ICAM-1 in blood and the bronchoalveolar lavage fluid.Asthma mechanism of prescription of Patecy Lung and preventing asthma was probed through cell and molecular biology level,and this also gave a foundation for the development clinical of traditional Chinese compound prescription to prevent asthma.
Methods
1、In vivo experimental:first,cells of big mouse were differential counted,then contents of Eotaxin and ICAM-1 of supernatant fluid of cells were surveyed and evaluated by ELISA.Contents of IgE were detected by dfferential blood count and radioimmunoassay. Prepared tissue slice of Lung and bronchus from big mouse,and stained with Hematoxylin Eosin(HE),then Observed gas channel restructuring situation;Gene expression of Eotaxin and ICAM-1 from Lung and bronchial tube partial organization were investigated by immunohistochemistry.2、In vitro method:Including medicine blood serum was prepared;Proliferation level of Smooth muscle cell from bronchus were tested by MTT enzyme label ling and ICC method.
Results
1、In vivo experimental:1.1 The results were as follows: respiratory tract inflammation symptoms were improved obviously by prescription of Patecy Lung and preventing asthma,because quantity of WBC especially acidophilic leukocyte were cut down significantly decreased(P<0.01).It can also show that treatment and prevention function was realization by reduced the content of blood serum IgE.Those can give the Powerful experiment basis of Clinical practice against Bronchial tube asthma for prescription of Patecy Lung and preventing asthma.1.2 ELISA demonstration:the earlier period research indicated that the EOS was obviously controlled by prescription of Patecy Lung and preventing asthma, because the contents of Eotaxin and ICAM-1 of bronchia alveolus lavage fluid of control group were reduced obviously compared with that of normal group after Treatment.Remarkable pathology physiology characteristic of asthma inflammation was EOS infiltration.EOS hastened and collected to the inflammation spot were important pathology process in asthma illness,which were closely related to Eotaxin and ICAM-1.These results suggested that inhibitory action of Eotaxin and ICAM-1 possibly was as asthma's mechanism function of prescription of Patecy Lung and preventing asthma.1.3 HE dyeing demonstrated by Lung organization pathological section:After the antigen stimulated,the inflammatory of eosinophilic granulocyte and inflammatory cell of model group lung organization were increased obviously compared with that of the control group(P<0.01).
2、Vitro method:This experiment discovered that the PCNA expression's average light density of blood serum including medicine was obviously higher than that of control group among three groups:normal control,high and low(P<0.05).It had non-significance difference compared with that of Dexamethasone group,and the same result was discovered by MTT method.The experiment proved:ASMC of big mouse was obviously restrained by blood serum group with medicine of high and normal group,and the result was the same as that of Dexamethasone group,but no obviously effect of low group.Maybe medicine density leaded to the result. The ASMC inhibit function had enhancement tendency along with the response time.Maybe explained that asthma was prevented and controlled through inhibition of His and proliferation of ASMC,and certain dosage and time dependence were included.
Conclusions
1、Vivo experimental:Suppressing cough function(symptoms improved and the content of IgE、EOS and EOS of BALF in blood were dropped. Bronchial tube and lung morphology) and mechanism function(the Eotaxin of chemotactic factor and ICAM-1 of adhesion molecule were controlled)were Confirmed for prescription of Patecy Lung and preventing asthma.
2、Vitro experimental:For prescription of Patecy Lung and preventing asthma,Resistance asthma big mouse gas channel blocking function(Suppressed cell multiplication in the smooth muscle of bronchial tube) and mechanism(Suppressed smooth muscle cell's PCNA) were discovered.
3、Freeing lung and relieving asthma and also removing heat-phlegm were defined to asthma.
4、Experiment basis for the traditional Chinese compound prescription's development which relieving asthma was provided.
方法1、体内实验方法:取大鼠支气管肺泡灌洗液(BALF)进行细胞计数和分类,对其上清液以双抗夹心酶联免疫吸附(ELISA)法进行细胞因子Eotaxin、ICAM-1含量的测定;血细胞计数分类,放免法检测血中IgE含量;制备大鼠支气管及肺组织切片,HE染色,观察气道重构情况;免疫组化法检测肺及支气管局部组织Eotaxin、ICAM-1的表达。2、体外实验方法:含药血清制备;MTT酶标法、免疫细胞化学(ICC)法测支气管平滑肌细胞的增殖水平,以了解该方对抗哮喘气道重构的作用。
结果1、体内试验:1.1实验结果显示畅肺防喘方可显著降低WBC数量,尤其是嗜酸性细胞(P<0.01),说明该方可明显改善呼吸道炎性症状。实验结果还表明血清IgE的含量降低,说明其治疗和预防作用可能是通过此途径来实现的,为畅肺防喘方治疗支气管哮喘的临床应用提供了有力的实验依据。
1.2 ELISA法结果显示:与正常组比较模型组支气管肺泡灌洗液中Eotaxin、ICAM-1均显著升高,经治疗后,上述指标均显著降低。说明畅肺防喘方可显著抑制哮喘大鼠Eotaxin、ICAM-1表达。前期研究表明,该方对EOS的抑制作用较为明显。EOS浸润是哮喘炎症的显著病理生理特征,EOS向炎症部位趋化、募集,是哮喘病症中重要的病理过程,其过程机制与Eotaxin、ICAM-1等关系密切。结果提示,对Eotaxin、ICAM-1的抑制作用可能是畅肺防喘方治疗哮喘的作用机制之一。
1.3肺组织病理切片HE染色显示,抗原激发后模型组肺组织嗜酸性粒细胞和炎症细胞浸润与对照组相比有明显增多(P<0.01)。
2、体外实验:本实验发现畅肺防喘方高、中、小剂量组含药血清对支气管平滑肌增殖细胞核抗原(PCNA)表达的平均光密度明显高于对照组(P<0.05),与地塞米松组无显著性差异(P>0.05),它与MTT法观察结果一致。本次实验证明,与对照组比较,畅肺防喘方高、中剂量含药血清组能明显抑制大鼠支气管平滑肌细胞(ASMC)的增殖,与地塞米松含药血清组比较无显著性差异,而畅肺防喘方小剂量含药血清组则无明显作用,考虑可能与药物浓度有关。且随着作用时间的延长,含药血清对支气管平滑肌细胞的抑制作用有增强趋势。说明畅肺防喘方可能通过抑制组胺(His)促ASMC增殖作用而达到防治哮喘的效果,且存在一定的剂量、时间依赖关系。
结论1、体内实验:证实了畅肺防喘方的平喘作用(症状改善,血中IgE、EOS,BALF中EOS含量下降,支气管及肺形态学的变化)和作用机制(抑制趋化因子Eotaxin和粘附分子ICAM-1的表达)。
2、体外实验:运用血清药理学方法证实了畅肺防喘方有较好的抗哮喘大鼠气道重构的作用(抑制支气管平滑肌细胞增殖)和抑制平滑肌细胞的PCNA的作用。
3、明确了宣肺平喘、清热化痰法对哮喘的防治作用机制。
4、为进一步开发具有较好疗效的中药复方制剂,提供了实验依据。
objective
The Prescription of Patecy Lung and preventing asthma,which is used in clinical medicine is preliminary exploration in immunization for many years,and effect was Significantly. Inhibition of value-added for smooth muscle cell of bronchus were studied though Serum pharmacology method in-vitro method assay; Thought in-vivo experiment,the affect of preventing asthma and lung morphology to the model asthma pig mouse which were medicated by this Prescription were observed.The diversification of EOS、IgE、Eotaxin of correlation factor and expression level changes of adhesion molecule ICAM-1 in blood and the bronchoalveolar lavage fluid.Asthma mechanism of prescription of Patecy Lung and preventing asthma was probed through cell and molecular biology level,and this also gave a foundation for the development clinical of traditional Chinese compound prescription to prevent asthma.
Methods
1、In vivo experimental:first,cells of big mouse were differential counted,then contents of Eotaxin and ICAM-1 of supernatant fluid of cells were surveyed and evaluated by ELISA.Contents of IgE were detected by dfferential blood count and radioimmunoassay. Prepared tissue slice of Lung and bronchus from big mouse,and stained with Hematoxylin Eosin(HE),then Observed gas channel restructuring situation;Gene expression of Eotaxin and ICAM-1 from Lung and bronchial tube partial organization were investigated by immunohistochemistry.2、In vitro method:Including medicine blood serum was prepared;Proliferation level of Smooth muscle cell from bronchus were tested by MTT enzyme label ling and ICC method.
Results
1、In vivo experimental:1.1 The results were as follows: respiratory tract inflammation symptoms were improved obviously by prescription of Patecy Lung and preventing asthma,because quantity of WBC especially acidophilic leukocyte were cut down significantly decreased(P<0.01).It can also show that treatment and prevention function was realization by reduced the content of blood serum IgE.Those can give the Powerful experiment basis of Clinical practice against Bronchial tube asthma for prescription of Patecy Lung and preventing asthma.1.2 ELISA demonstration:the earlier period research indicated that the EOS was obviously controlled by prescription of Patecy Lung and preventing asthma, because the contents of Eotaxin and ICAM-1 of bronchia alveolus lavage fluid of control group were reduced obviously compared with that of normal group after Treatment.Remarkable pathology physiology characteristic of asthma inflammation was EOS infiltration.EOS hastened and collected to the inflammation spot were important pathology process in asthma illness,which were closely related to Eotaxin and ICAM-1.These results suggested that inhibitory action of Eotaxin and ICAM-1 possibly was as asthma's mechanism function of prescription of Patecy Lung and preventing asthma.1.3 HE dyeing demonstrated by Lung organization pathological section:After the antigen stimulated,the inflammatory of eosinophilic granulocyte and inflammatory cell of model group lung organization were increased obviously compared with that of the control group(P<0.01).
2、Vitro method:This experiment discovered that the PCNA expression's average light density of blood serum including medicine was obviously higher than that of control group among three groups:normal control,high and low(P<0.05).It had non-significance difference compared with that of Dexamethasone group,and the same result was discovered by MTT method.The experiment proved:ASMC of big mouse was obviously restrained by blood serum group with medicine of high and normal group,and the result was the same as that of Dexamethasone group,but no obviously effect of low group.Maybe medicine density leaded to the result. The ASMC inhibit function had enhancement tendency along with the response time.Maybe explained that asthma was prevented and controlled through inhibition of His and proliferation of ASMC,and certain dosage and time dependence were included.
Conclusions
1、Vivo experimental:Suppressing cough function(symptoms improved and the content of IgE、EOS and EOS of BALF in blood were dropped. Bronchial tube and lung morphology) and mechanism function(the Eotaxin of chemotactic factor and ICAM-1 of adhesion molecule were controlled)were Confirmed for prescription of Patecy Lung and preventing asthma.
2、Vitro experimental:For prescription of Patecy Lung and preventing asthma,Resistance asthma big mouse gas channel blocking function(Suppressed cell multiplication in the smooth muscle of bronchial tube) and mechanism(Suppressed smooth muscle cell's PCNA) were discovered.
3、Freeing lung and relieving asthma and also removing heat-phlegm were defined to asthma.
4、Experiment basis for the traditional Chinese compound prescription's development which relieving asthma was provided.
引文
[1]Justice JP,BorchersMT,Crosby JR,etal Ablation of eosinophils leadsa reduction allergen induced pulmonary[J].Am J Phsiol Lung CelMolPhysiol,2003,248(1):169-178.
[2]Gibson PG,Dolovich J,Girgis-Gabaardo A,etal.The inflammatory response of asthma exacerbation:changes in circulating eosinophils,basophils and their progenitors.Clin Exp Allergy,1990,20:661-668.
[3]Jose PJ,Griffiths-Johnson DA,Collins PD,et al.Eotaxin:a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation.J Exp Med,1994,179:881-887.
[4]Brown JR,Kleimberg J,Marini M,et al.Kinetics of eotaxinexpression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage(BAL) of asthmatic patients after allergen inhalation.Clin Exp Immunol.1998,114(2):137-46.
[5]曾译戎,崔德健.嗜酸粒细胞特异性趋化因子Eotaxin.国外医学呼吸系统分册[M],2003,23(2):66-69.
[6]赵振东,刘镜愉,等.邻苯二甲酸酐哮喘大鼠模型制备及其肺组织中细胞间粘附分子-1mRNA的表达[J].北京医科大学学报,1998,30(6):521-524.
[7]李慧,等.肺表面活性物质对哮喘大鼠粘附分子的影响[J].实用医杂志,2003,(4):288-289.
[8]商艳,等.细胞粘附分子和支气管哮喘.国外医学呼吸系统分[M],2001,21(3):140-141,144.
[9]赵琛,冯岩.激素依赖型哮喘的中医中药治疗[J].吉药,2002,22(2):19.
[10]张芬兰,等.疏肝理肺法治疗支气管哮喘30例临床观察[J].长春中 医学院学报,2002;(3):13.
[11]朱建秀,等.自拟哮喘方加减治疗支气管哮喘58例[J].辽宁中医杂志,2002,29(10):595-596.
[12]刘昌鹏,刘小凡.射干麻黄汤化裁治疗婴幼儿哮喘急性发作102例[J].四川中医,2005,23(7):90-91.
[13]周璟.麻杏石甘汤加味治疗哮喘40例临床观察[J].天津中医学院学报,2002,21(2):23.
[1]钱振福,崔芳囡.国内支气管哮喘气道重塑动物模型的研究进展[J].医学综述,MedicalRecapitulate,Jan 2009,Vo.1 15,No.1.
[2]Wardlaw AJ.Molecular basis for selective eosinophil trafficking in asthma:A multistep paradigm.J Allergy Clin Immunol.1999;104(5):917-26.
[3]Gibson PG,Dolovich J,Girgis-Gabaardo A,et al.The inflammatory response of asthma exacerbation:changes in circulating eosinophils,basophils and their progenitors.Clin Exp Allergy,1990,20:661-668.
[4]王忆勤,李福凤,燕海霞,等.复方麻琴汤对哮喘患儿免疫功能的调节作用[J].上海中医药杂志,2 006,40(4):37-38.
[5]周丽莎,朱书秀,涂乾.潜伏期天灸对哮喘模型大鼠的影响[J].陕西中医,2005,26(5):471-472.
[6]刘中娟,任艳丽,林嘉友,等.哮喘患者血清嗜酸性粒细胞趋化蛋白测定及其临床诊断价值[J].中国医学科学院学报,2004,26(3):298-301.
[7]付杰伟,陈平,向旭东.嗜酸性粒细胞趋化因子在哮喘、慢性支气管炎患者诱导痰中的表达及其与气道炎症的关系[J].中华结核呼吸杂志,2002,25(1):29-32.
[8]PengQ,Matsuda T,Hirst SJ.Signaling pathways regula-ting interleukin-13-stimulated chemokine release fromairway smoothmuscle[J].Am J.Respir CritCareMed,2004,169(5):596-603.
[9]Mattes J,Foster PS.Regulation of eosinophil migrationand Th2cell function by IL-5 and eotaxin[J].CurtDrug Targets Inflamm Allergy,2003,2(2):169-174.
[10]王成国,薛克营,程立,等.丹参注射液对哮喘大鼠肺IL-13和嗜酸粒细胞趋化因子表达的影响[J].郧阳医学院学报,2008;27(3): 205.
[11]Albanesi C,Pastore S,Fanales-Belasio E,et al.Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release incultured human kerationcytes[J].Clin Exp Allergy,1998,(28):101.
[12]曹国强,杨肇亨.糖皮质激素对哮喘豚鼠支气管粘膜中ICAM-1、E-选择素表达的影响[J].第三军医大学学报,1997,19(6):544.
[13]李冀,旺建伟,徐国亭.苏子降气汤对哮喘模型EOS的数量及作用机理的影响[J].中医药信息,2004;21(6):27.
[1]李仪奎.中药血清药理学试验方法的若干问题.中药新药与临床药理,1999,10(2):95-98.
[2]Ross R.The growth of smooth muscle cell in culture and formation of elastic fibers.J Cell Biol,1991,50:172-186.
[3]司徒镇强主编.细胞培养.北京:世界图书出版公司,2005,200.
[4]Ross R.The growth of smooth muscle cell in culture and formation of elastic fibers.J Cell Biol,1991,50:180-186.
[5]Glassberg MK,ErgulA,WannerA,et al Endothelin-lpromotes mitogenesisin airway smooth muscle cells.Am J Respir Cell Mol Biol,1994,10:316.
[6]Pang LH,Knox AJ.PGE2 release by bradykinin inhu-man airway smooth muscle(ells:involvement of cyclooxygenase2induction.Am J Physiol,1997,273(17):L1132-L1140.
[7]Johnson RA,Black JL,Carlin S,etal.The Production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture.Am J Re-spin Crit Care Med,2000,162:2145 2151.
[8]唐槐静.段胜仲,等.胎儿动脉平滑肌细胞培养方法的研究.湖北医科大学学报,1999,20(2):89.
[9]张媛莉,何建猷,梁标,等.雷公藤甲素对体外培养大鼠气道平滑肌细胞增殖及原癌基因的影响,中国药学杂志,2003,38(5):348-350
[10]弗雷谢尼,章静波,徐存拴(译).动物细胞培养-基本技术指南 第4版 北京:科学出版社,2004.116-120.
[1]郭云霞.儿童哮喘证治的中医药研究摘要[J].中医药学刊,2002,20(2):201
[2]洪广祥.哮证治疗之我见[J].中医杂志,1998,29(3):7
[3]王根军.从风痰论治急性发作期支气管哮喘[J]·中华实用中西医杂志,2005,18(13):233
[4]沈自尹.补肾法预防哮喘的变态和非变态反应机制研究[J].中西医结合杂志,1989,9(2):82
[5]史锁芳.哮喘“夙根”探讨[J].中医药学报,1994,(3):6
[6]韦衮政,敖素华.胡天成治疗小儿哮喘经验举隅[J].辽宁中医杂志,2002,29(10):585
[7]彭红星.陈陶后教授治疗小儿哮喘经验[J].山西中医,1995,(2):5
[8]张伟,邵雨萌.再论哮喘从瘀论治[J].湖南中医学院学报,2004,24(3):24
[9]朱鹏.复元活血汤治疗哮喘12例疗效观察[J].江西中医药,1995,(5):33
[10]廖世才.小儿哮喘活血化瘀法治疗体会[J].江西中医药,1997,28(6):33
[11]洪霞,廖宝军.从痰瘀论治小儿哮喘116例分析.陕西中医函授,2000,(5):41
[12]周仲瑛.哮喘杂谈.江苏中医,2000,21(18):15
[13]洪广祥.哮证治疗之我见[J].中医杂志,1988,29(3):7
[14]胡国俊.胡翘武治疗支气管哮喘的经验[J].中国医药学报,1993,8(5):56
[15]张建明.哮喘有因血虚论[J].中医杂志,1992,33(9):57
[16]沈俊元.中西医结合治疗小儿支气管哮喘36例[J].中国中西医结合杂志,1995,15(12):754
[17]汪受传主编.中医儿科学[M].北京:中国中医药出版社,2002.75
[18]高淑英.哮喘从肝肺论治探讨[J].中国中医药信息杂志,2006,13(8):77
[19]武维屏,崔红生.试论支气管哮喘从肝论治的生理病理学基础[J].中国中医基础医学杂志,2002,8(10):7-8
[20]毛玉燕.钱育寿.治疗小儿哮喘的经验.河北中医,2000,22(3):174.
[21]王青海,黄琳,等.胃不和与支气管哮喘的关系初探[J].广东医学,2001,22(8):755.
[22]许建中,吴银根,李明华.中西医结合哮喘病学[M].北京:人民卫生出版社.2001,7.
[23]刘小凡,司东波.小儿哮喘间歇期的证治探讨[J].中国中医急症,2004,13(5):29.
[24]罗玉华.小儿哮喘的中医辨证治疗.四川中医,2002,20(1):17.
[25]曹宏,陈鲁.补肾培元法治疗小儿哮喘体会[J].陕西中医,2000,21(8):3.
[26]范钰,万救钢,万铭,等.黄芪注射液对哮喘患者气道反应性的影响[J].新中医,2001,33(4):27.
[27]王孟清,朱哗,舒兰,等.截哮口服液防治病毒诱发小儿哮喘的临床研究[J].中国中西医结合杂志,2003,23(12):902-904.
[28]周志荣.复方太子参止咳益气散治疗支气管哮喘2180例疗效观察.中国民族医药杂志,2005(5):12.
[29]杨明升.儿康宁佐治婴幼儿哮喘缓解期疗效观察[J].实用中西医结合杂志,1998,11(1):52.
[30]郑礼林,倪陈,陆伟,等.0～14岁儿童支气管哮喘流行病学调查[J].疾病控制杂志2003,7(005):408-410.
[31]高进,郭俊晓.儿童支气管哮喘发病诱因和过敏原分析[J].中国误诊学杂志.2004,4(011):1826-1827.
[32]陈树室.儿科学新理论与新技术[Z].上海:上海科技教育出版社,1996.
[33]吴梓梁.实用临床儿科学[J].广州:广州出版社.1998,1664.
[34]顾玉成.小儿支气管哮喘治疗进展[J].中华综合医学杂志.2003,5(007):90-92.
[35]陈育智.儿童支气管哮喘防治常规(试行)[J].中华儿科杂志.2004,42(002)100-106.
[36]ShefferAL.Glbal Strategy for Asthma Management and PreventionNHLBI[J]WHO WorkshoP RePort.National Institute of Heath,Bethesda Md.1995:95-3659
[37]支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育管理方案)[J].中华结核和呼吸杂志.2003,26(3):132-138.
[38]杨子妮,税源,计磊,等.吸入激素联合缓释茶碱与β2-受体激动剂治疗儿童哮喘比较[J].实用医药杂志(山东).2006,23(011):1305-1308.
[1]李明华.哮喘病学[M].北京人民卫生出版社,1998,44-45.
[2]崔新乐,朱之任.一氧化氮与哮喘[M],国外医学·呼吸系统分册[M],1996(16):1012.
[3]王宏长,李培成,吴银根,等.中药咳喘落对实验性哮喘豚鼠ECP和slCAM-1的影响[J].广东中医杂志,2000,2(3):1881.
[4]龙学明.细胞因子在支气管哮喘发病中的作用[J].广西中医学院学报,2000,17(4):831.
[5]蔡宛如,等.芍药甘草汤平喘和抗过敏的实验研究[J],中国中西医结合急救杂志,2000,11(6):341-342.
[6]王力宁,等.六味地黄丸协同必可酮对致敏豚鼠气道反应性和血嗜酸细胸的影响[J],广西中医药,2000,2(6):51-53.
[7]张建勇.火把花根片对哮喘豚鼠气道炎症的作用[J],贵州医药,2001,11(10):89-892.
[8]吴银根,徐重明,李培成.咳喘落对哮喘模型豚鼠外周血白细胞糖皮质激素受体影响的实验研究[J].中国中医基础医学杂志,1997,3(6):361.
[9]FishJEPetersSP.AirwayremodelingandPersistentairwayobstruetio ninasthma[J].JAllergyelinImmunol.1999,104:509.
[10]薛汉荣,等.益气温阳护卫汤对缓解期哮喘患者气道反应性的影响及用机理研究[J],中国医学学报,2004,19(8):477.
[11]李彤.平哮合剂对哮喘气道高反应性的影响[J],山西中医,2001,17(3):44.
[12]王长征,等.致敏豚鼠的气道高反应机理及药物干预作用[J],中国病理生理杂志,1997,13(1):8.
[13]蒋毅,杜永成,刘立新,等.雷公藤多甙下调IL-β1诱导的呼吸道上皮细胞TGF-β1的表达[J].山西医科大学学报,2006,37(1):25-28.
[14]王文建,杨莉,王西华,等.川芎嗪对大鼠支气管哮喘模型气道重塑的影响及机制[J].中华结核和呼吸杂志,2004,27(12):833-836.
[15]王丽新,吴银根.止喘胶囊对哮喘大鼠气道TGF-β1转导的干预作用[J].上海中医药杂志,2005,38(8):50-52.
[16]王三萍,熊金海,苏怡凡,等.姜黄素对哮喘大鼠气道胶原沉积及转化生长因子β1表达的影响[J].临床儿科杂志,2005,23(9):659-661
[17]王琳,刘方洲,高寒,等.小青龙汤对哮喘大鼠ET1及NO的作用研究[J].中药药理与临床,2002,18(5):7-9.
[18]张有志,聂惠民,张宁,等.桂枝加厚朴杏子汤对过敏性哮喘豚鼠肿瘤坏死因子α、内皮素1的影响.北京中医药大学学报[J],2002,23(2):3-4.
[19]江珊,梁仁.中药地龙药理与哮喘气道重建相关性研究[J].广东药学院学报,2004,20(1):60-62.
[20]刘鑫,戴爱国,樊天会,等.柴朴汤对哮喘豚鼠肺内嗜酸粒细胞凋亡及气道重塑的影响[J].四川中医.2005,23(6):15-16.
[21]HoganSp,KoskinerA,MatthaeiKl,eta.Interleukin-5-produecing.D 4~+TeellspalyaPivotalroleinaeroallegen-indueedeosinoPhilia,bronehialhyPerreaetivityandlungdamageinmieeAm[J].ResPirCri tCareMedl998,157(1):210-218.
[22]张全爱,等.哮喘模型豚鼠变态反应机制的实验研究[J],甘肃中医学院学报,2003,20(4):16-17.
[23]魏庆宇,等.加味玉屏风散对哮喘大鼠支气管上皮IcAM-1的表达及BALF中n-5含量的影响[J],中国实验方剂学杂志,2001,7(5):40-42.
[24]郭素华,等.加味肾气丸对Th1,Th2细胞凋亡及细胞因子表达影响的研究[J],贵阳中医学院学报,2004,26(1):48·50.
[25]王宏长,等.中药咳喘落对实验性哮喘豚鼠EcP和slcAM-1的影响[J],广东医学,2000,21(3):188-190.
[26]赵育芳,等.太子健Ⅱ对哮喘豚鼠白细胞介素5、P-选择素的影响[J],山西医药杂志,2004,33(7):565-567.
[27]王长征,等.雷公藤甲素对哮喘动物模型气道反应的观察[J],中华医学杂志,1996,76(1):68.
[28]赵晓东,等.黄蔑对哮喘患儿INF-γ,IL-4及IgE亚类体外产生的影响[J],中国实用儿科杂志,1997,12(6):345.
[29]张在期,等.小青龙汤对哮喘小鼠肺组织Th1/Th2作用的实验研究[J],中国中西医结合急救杂志,2004,11(6):368.
[30]薛汉荣,等.益气温阳护卫汤对哮喘豚鼠BALF中Th1,Th2细胞因子产生及调节的作用,中国医药学报,2002,17(3):152.
[31]壮健,等.消喘膏贴敷对哮喘豚鼠Th1,Th2类细胞因子的影响[J],四川中医,2003,21(6):13.
[32]何丽,郭盛,熊先敏.扶正化痰法对哮喘豚鼠血清IL-8、TNF-α的影响研究[J].中医药学刊,2003,21(2):2801.
[33]莫碧文,王昌明,于方,等.豚鼠实验性支气管哮喘时支气管肺泡灌洗液及血浆中IL-8水平的检测[J].中国病理生理杂志,2002,18(5):562.
[34]卫宏长,吴红梅,方泓,等.补肾健脾固本法治疗支气管哮喘的实验研究[J].上海中医药大学学报,2001,15(4):391.
[35]刘建秋,吴树亮,李竹英.喘康宁冲剂对支气管哮喘嗜酸粒细胞凋亡的实验研究[J].ITCM,2003,20(1):561.
[36]邢向晖,徐宁.平喘方对哮喘大鼠平喘作用的实验研究[J].中国中医药信息杂志.2002,9(12):171.
[37]HamannKJ,VieriaJE,HalaykoAJetalFas.eross-linkingindueesaPoP tosisiinhu-manairwaySmoothmuseleeellAm[J].PhysiolIungeellMo lPhysiol.2000,278(3):L618-628.
[38]刘贵颖,等.咳喘方对哮喘豚鼠肺组织嗜酸细胞凋亡的影响[J],天津中医药2004,21(4):315-317.
[39]伍参荣,等.治喘贴对实验豚鼠嗜酸粒细胞凋亡和对白细胞介素-5的影响[J],中华微生物学和免疫学杂志,2004,24(7):549.
[40]方向明,等.平喘合剂对哮喘豚鼠T淋巴细胞凋亡的影响[J],中国中医基础医学杂志,2003,9(3):184-186.
[41]林科雄,雷公藤对哮喘豚鼠GM-CSF基因转录的影响与作用机制[J],中国免疫学杂志,2000,(9):325-327.
[42]李志奎,等.雷公藤甲素对哮喘豚鼠嗜酸性粒细胞凋亡及Fas、Bcl、MRNA表达的影响[J],中国新药与临床杂志,2002,5(5):261·262.
[43]王宏长,等.中药哮喘落对哮喘大鼠肺组织白细胞介素-4、11-SMRNA 影响及相关性研究[J],广东医学,2000,21(2):107.
[44]范欣生,等.复方辛夷平喘液对哮喘豚鼠肺内ICA及淋巴细胞fas表达的影响[J],中华结核和呼吸杂志,2002,25(5):280.
[2]Gibson PG,Dolovich J,Girgis-Gabaardo A,etal.The inflammatory response of asthma exacerbation:changes in circulating eosinophils,basophils and their progenitors.Clin Exp Allergy,1990,20:661-668.
[3]Jose PJ,Griffiths-Johnson DA,Collins PD,et al.Eotaxin:a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation.J Exp Med,1994,179:881-887.
[4]Brown JR,Kleimberg J,Marini M,et al.Kinetics of eotaxinexpression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage(BAL) of asthmatic patients after allergen inhalation.Clin Exp Immunol.1998,114(2):137-46.
[5]曾译戎,崔德健.嗜酸粒细胞特异性趋化因子Eotaxin.国外医学呼吸系统分册[M],2003,23(2):66-69.
[6]赵振东,刘镜愉,等.邻苯二甲酸酐哮喘大鼠模型制备及其肺组织中细胞间粘附分子-1mRNA的表达[J].北京医科大学学报,1998,30(6):521-524.
[7]李慧,等.肺表面活性物质对哮喘大鼠粘附分子的影响[J].实用医杂志,2003,(4):288-289.
[8]商艳,等.细胞粘附分子和支气管哮喘.国外医学呼吸系统分[M],2001,21(3):140-141,144.
[9]赵琛,冯岩.激素依赖型哮喘的中医中药治疗[J].吉药,2002,22(2):19.
[10]张芬兰,等.疏肝理肺法治疗支气管哮喘30例临床观察[J].长春中 医学院学报,2002;(3):13.
[11]朱建秀,等.自拟哮喘方加减治疗支气管哮喘58例[J].辽宁中医杂志,2002,29(10):595-596.
[12]刘昌鹏,刘小凡.射干麻黄汤化裁治疗婴幼儿哮喘急性发作102例[J].四川中医,2005,23(7):90-91.
[13]周璟.麻杏石甘汤加味治疗哮喘40例临床观察[J].天津中医学院学报,2002,21(2):23.
[1]钱振福,崔芳囡.国内支气管哮喘气道重塑动物模型的研究进展[J].医学综述,MedicalRecapitulate,Jan 2009,Vo.1 15,No.1.
[2]Wardlaw AJ.Molecular basis for selective eosinophil trafficking in asthma:A multistep paradigm.J Allergy Clin Immunol.1999;104(5):917-26.
[3]Gibson PG,Dolovich J,Girgis-Gabaardo A,et al.The inflammatory response of asthma exacerbation:changes in circulating eosinophils,basophils and their progenitors.Clin Exp Allergy,1990,20:661-668.
[4]王忆勤,李福凤,燕海霞,等.复方麻琴汤对哮喘患儿免疫功能的调节作用[J].上海中医药杂志,2 006,40(4):37-38.
[5]周丽莎,朱书秀,涂乾.潜伏期天灸对哮喘模型大鼠的影响[J].陕西中医,2005,26(5):471-472.
[6]刘中娟,任艳丽,林嘉友,等.哮喘患者血清嗜酸性粒细胞趋化蛋白测定及其临床诊断价值[J].中国医学科学院学报,2004,26(3):298-301.
[7]付杰伟,陈平,向旭东.嗜酸性粒细胞趋化因子在哮喘、慢性支气管炎患者诱导痰中的表达及其与气道炎症的关系[J].中华结核呼吸杂志,2002,25(1):29-32.
[8]PengQ,Matsuda T,Hirst SJ.Signaling pathways regula-ting interleukin-13-stimulated chemokine release fromairway smoothmuscle[J].Am J.Respir CritCareMed,2004,169(5):596-603.
[9]Mattes J,Foster PS.Regulation of eosinophil migrationand Th2cell function by IL-5 and eotaxin[J].CurtDrug Targets Inflamm Allergy,2003,2(2):169-174.
[10]王成国,薛克营,程立,等.丹参注射液对哮喘大鼠肺IL-13和嗜酸粒细胞趋化因子表达的影响[J].郧阳医学院学报,2008;27(3): 205.
[11]Albanesi C,Pastore S,Fanales-Belasio E,et al.Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release incultured human kerationcytes[J].Clin Exp Allergy,1998,(28):101.
[12]曹国强,杨肇亨.糖皮质激素对哮喘豚鼠支气管粘膜中ICAM-1、E-选择素表达的影响[J].第三军医大学学报,1997,19(6):544.
[13]李冀,旺建伟,徐国亭.苏子降气汤对哮喘模型EOS的数量及作用机理的影响[J].中医药信息,2004;21(6):27.
[1]李仪奎.中药血清药理学试验方法的若干问题.中药新药与临床药理,1999,10(2):95-98.
[2]Ross R.The growth of smooth muscle cell in culture and formation of elastic fibers.J Cell Biol,1991,50:172-186.
[3]司徒镇强主编.细胞培养.北京:世界图书出版公司,2005,200.
[4]Ross R.The growth of smooth muscle cell in culture and formation of elastic fibers.J Cell Biol,1991,50:180-186.
[5]Glassberg MK,ErgulA,WannerA,et al Endothelin-lpromotes mitogenesisin airway smooth muscle cells.Am J Respir Cell Mol Biol,1994,10:316.
[6]Pang LH,Knox AJ.PGE2 release by bradykinin inhu-man airway smooth muscle(ells:involvement of cyclooxygenase2induction.Am J Physiol,1997,273(17):L1132-L1140.
[7]Johnson RA,Black JL,Carlin S,etal.The Production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture.Am J Re-spin Crit Care Med,2000,162:2145 2151.
[8]唐槐静.段胜仲,等.胎儿动脉平滑肌细胞培养方法的研究.湖北医科大学学报,1999,20(2):89.
[9]张媛莉,何建猷,梁标,等.雷公藤甲素对体外培养大鼠气道平滑肌细胞增殖及原癌基因的影响,中国药学杂志,2003,38(5):348-350
[10]弗雷谢尼,章静波,徐存拴(译).动物细胞培养-基本技术指南 第4版 北京:科学出版社,2004.116-120.
[1]郭云霞.儿童哮喘证治的中医药研究摘要[J].中医药学刊,2002,20(2):201
[2]洪广祥.哮证治疗之我见[J].中医杂志,1998,29(3):7
[3]王根军.从风痰论治急性发作期支气管哮喘[J]·中华实用中西医杂志,2005,18(13):233
[4]沈自尹.补肾法预防哮喘的变态和非变态反应机制研究[J].中西医结合杂志,1989,9(2):82
[5]史锁芳.哮喘“夙根”探讨[J].中医药学报,1994,(3):6
[6]韦衮政,敖素华.胡天成治疗小儿哮喘经验举隅[J].辽宁中医杂志,2002,29(10):585
[7]彭红星.陈陶后教授治疗小儿哮喘经验[J].山西中医,1995,(2):5
[8]张伟,邵雨萌.再论哮喘从瘀论治[J].湖南中医学院学报,2004,24(3):24
[9]朱鹏.复元活血汤治疗哮喘12例疗效观察[J].江西中医药,1995,(5):33
[10]廖世才.小儿哮喘活血化瘀法治疗体会[J].江西中医药,1997,28(6):33
[11]洪霞,廖宝军.从痰瘀论治小儿哮喘116例分析.陕西中医函授,2000,(5):41
[12]周仲瑛.哮喘杂谈.江苏中医,2000,21(18):15
[13]洪广祥.哮证治疗之我见[J].中医杂志,1988,29(3):7
[14]胡国俊.胡翘武治疗支气管哮喘的经验[J].中国医药学报,1993,8(5):56
[15]张建明.哮喘有因血虚论[J].中医杂志,1992,33(9):57
[16]沈俊元.中西医结合治疗小儿支气管哮喘36例[J].中国中西医结合杂志,1995,15(12):754
[17]汪受传主编.中医儿科学[M].北京:中国中医药出版社,2002.75
[18]高淑英.哮喘从肝肺论治探讨[J].中国中医药信息杂志,2006,13(8):77
[19]武维屏,崔红生.试论支气管哮喘从肝论治的生理病理学基础[J].中国中医基础医学杂志,2002,8(10):7-8
[20]毛玉燕.钱育寿.治疗小儿哮喘的经验.河北中医,2000,22(3):174.
[21]王青海,黄琳,等.胃不和与支气管哮喘的关系初探[J].广东医学,2001,22(8):755.
[22]许建中,吴银根,李明华.中西医结合哮喘病学[M].北京:人民卫生出版社.2001,7.
[23]刘小凡,司东波.小儿哮喘间歇期的证治探讨[J].中国中医急症,2004,13(5):29.
[24]罗玉华.小儿哮喘的中医辨证治疗.四川中医,2002,20(1):17.
[25]曹宏,陈鲁.补肾培元法治疗小儿哮喘体会[J].陕西中医,2000,21(8):3.
[26]范钰,万救钢,万铭,等.黄芪注射液对哮喘患者气道反应性的影响[J].新中医,2001,33(4):27.
[27]王孟清,朱哗,舒兰,等.截哮口服液防治病毒诱发小儿哮喘的临床研究[J].中国中西医结合杂志,2003,23(12):902-904.
[28]周志荣.复方太子参止咳益气散治疗支气管哮喘2180例疗效观察.中国民族医药杂志,2005(5):12.
[29]杨明升.儿康宁佐治婴幼儿哮喘缓解期疗效观察[J].实用中西医结合杂志,1998,11(1):52.
[30]郑礼林,倪陈,陆伟,等.0～14岁儿童支气管哮喘流行病学调查[J].疾病控制杂志2003,7(005):408-410.
[31]高进,郭俊晓.儿童支气管哮喘发病诱因和过敏原分析[J].中国误诊学杂志.2004,4(011):1826-1827.
[32]陈树室.儿科学新理论与新技术[Z].上海:上海科技教育出版社,1996.
[33]吴梓梁.实用临床儿科学[J].广州:广州出版社.1998,1664.
[34]顾玉成.小儿支气管哮喘治疗进展[J].中华综合医学杂志.2003,5(007):90-92.
[35]陈育智.儿童支气管哮喘防治常规(试行)[J].中华儿科杂志.2004,42(002)100-106.
[36]ShefferAL.Glbal Strategy for Asthma Management and PreventionNHLBI[J]WHO WorkshoP RePort.National Institute of Heath,Bethesda Md.1995:95-3659
[37]支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育管理方案)[J].中华结核和呼吸杂志.2003,26(3):132-138.
[38]杨子妮,税源,计磊,等.吸入激素联合缓释茶碱与β2-受体激动剂治疗儿童哮喘比较[J].实用医药杂志(山东).2006,23(011):1305-1308.
[1]李明华.哮喘病学[M].北京人民卫生出版社,1998,44-45.
[2]崔新乐,朱之任.一氧化氮与哮喘[M],国外医学·呼吸系统分册[M],1996(16):1012.
[3]王宏长,李培成,吴银根,等.中药咳喘落对实验性哮喘豚鼠ECP和slCAM-1的影响[J].广东中医杂志,2000,2(3):1881.
[4]龙学明.细胞因子在支气管哮喘发病中的作用[J].广西中医学院学报,2000,17(4):831.
[5]蔡宛如,等.芍药甘草汤平喘和抗过敏的实验研究[J],中国中西医结合急救杂志,2000,11(6):341-342.
[6]王力宁,等.六味地黄丸协同必可酮对致敏豚鼠气道反应性和血嗜酸细胸的影响[J],广西中医药,2000,2(6):51-53.
[7]张建勇.火把花根片对哮喘豚鼠气道炎症的作用[J],贵州医药,2001,11(10):89-892.
[8]吴银根,徐重明,李培成.咳喘落对哮喘模型豚鼠外周血白细胞糖皮质激素受体影响的实验研究[J].中国中医基础医学杂志,1997,3(6):361.
[9]FishJEPetersSP.AirwayremodelingandPersistentairwayobstruetio ninasthma[J].JAllergyelinImmunol.1999,104:509.
[10]薛汉荣,等.益气温阳护卫汤对缓解期哮喘患者气道反应性的影响及用机理研究[J],中国医学学报,2004,19(8):477.
[11]李彤.平哮合剂对哮喘气道高反应性的影响[J],山西中医,2001,17(3):44.
[12]王长征,等.致敏豚鼠的气道高反应机理及药物干预作用[J],中国病理生理杂志,1997,13(1):8.
[13]蒋毅,杜永成,刘立新,等.雷公藤多甙下调IL-β1诱导的呼吸道上皮细胞TGF-β1的表达[J].山西医科大学学报,2006,37(1):25-28.
[14]王文建,杨莉,王西华,等.川芎嗪对大鼠支气管哮喘模型气道重塑的影响及机制[J].中华结核和呼吸杂志,2004,27(12):833-836.
[15]王丽新,吴银根.止喘胶囊对哮喘大鼠气道TGF-β1转导的干预作用[J].上海中医药杂志,2005,38(8):50-52.
[16]王三萍,熊金海,苏怡凡,等.姜黄素对哮喘大鼠气道胶原沉积及转化生长因子β1表达的影响[J].临床儿科杂志,2005,23(9):659-661
[17]王琳,刘方洲,高寒,等.小青龙汤对哮喘大鼠ET1及NO的作用研究[J].中药药理与临床,2002,18(5):7-9.
[18]张有志,聂惠民,张宁,等.桂枝加厚朴杏子汤对过敏性哮喘豚鼠肿瘤坏死因子α、内皮素1的影响.北京中医药大学学报[J],2002,23(2):3-4.
[19]江珊,梁仁.中药地龙药理与哮喘气道重建相关性研究[J].广东药学院学报,2004,20(1):60-62.
[20]刘鑫,戴爱国,樊天会,等.柴朴汤对哮喘豚鼠肺内嗜酸粒细胞凋亡及气道重塑的影响[J].四川中医.2005,23(6):15-16.
[21]HoganSp,KoskinerA,MatthaeiKl,eta.Interleukin-5-produecing.D 4~+TeellspalyaPivotalroleinaeroallegen-indueedeosinoPhilia,bronehialhyPerreaetivityandlungdamageinmieeAm[J].ResPirCri tCareMedl998,157(1):210-218.
[22]张全爱,等.哮喘模型豚鼠变态反应机制的实验研究[J],甘肃中医学院学报,2003,20(4):16-17.
[23]魏庆宇,等.加味玉屏风散对哮喘大鼠支气管上皮IcAM-1的表达及BALF中n-5含量的影响[J],中国实验方剂学杂志,2001,7(5):40-42.
[24]郭素华,等.加味肾气丸对Th1,Th2细胞凋亡及细胞因子表达影响的研究[J],贵阳中医学院学报,2004,26(1):48·50.
[25]王宏长,等.中药咳喘落对实验性哮喘豚鼠EcP和slcAM-1的影响[J],广东医学,2000,21(3):188-190.
[26]赵育芳,等.太子健Ⅱ对哮喘豚鼠白细胞介素5、P-选择素的影响[J],山西医药杂志,2004,33(7):565-567.
[27]王长征,等.雷公藤甲素对哮喘动物模型气道反应的观察[J],中华医学杂志,1996,76(1):68.
[28]赵晓东,等.黄蔑对哮喘患儿INF-γ,IL-4及IgE亚类体外产生的影响[J],中国实用儿科杂志,1997,12(6):345.
[29]张在期,等.小青龙汤对哮喘小鼠肺组织Th1/Th2作用的实验研究[J],中国中西医结合急救杂志,2004,11(6):368.
[30]薛汉荣,等.益气温阳护卫汤对哮喘豚鼠BALF中Th1,Th2细胞因子产生及调节的作用,中国医药学报,2002,17(3):152.
[31]壮健,等.消喘膏贴敷对哮喘豚鼠Th1,Th2类细胞因子的影响[J],四川中医,2003,21(6):13.
[32]何丽,郭盛,熊先敏.扶正化痰法对哮喘豚鼠血清IL-8、TNF-α的影响研究[J].中医药学刊,2003,21(2):2801.
[33]莫碧文,王昌明,于方,等.豚鼠实验性支气管哮喘时支气管肺泡灌洗液及血浆中IL-8水平的检测[J].中国病理生理杂志,2002,18(5):562.
[34]卫宏长,吴红梅,方泓,等.补肾健脾固本法治疗支气管哮喘的实验研究[J].上海中医药大学学报,2001,15(4):391.
[35]刘建秋,吴树亮,李竹英.喘康宁冲剂对支气管哮喘嗜酸粒细胞凋亡的实验研究[J].ITCM,2003,20(1):561.
[36]邢向晖,徐宁.平喘方对哮喘大鼠平喘作用的实验研究[J].中国中医药信息杂志.2002,9(12):171.
[37]HamannKJ,VieriaJE,HalaykoAJetalFas.eross-linkingindueesaPoP tosisiinhu-manairwaySmoothmuseleeellAm[J].PhysiolIungeellMo lPhysiol.2000,278(3):L618-628.
[38]刘贵颖,等.咳喘方对哮喘豚鼠肺组织嗜酸细胞凋亡的影响[J],天津中医药2004,21(4):315-317.
[39]伍参荣,等.治喘贴对实验豚鼠嗜酸粒细胞凋亡和对白细胞介素-5的影响[J],中华微生物学和免疫学杂志,2004,24(7):549.
[40]方向明,等.平喘合剂对哮喘豚鼠T淋巴细胞凋亡的影响[J],中国中医基础医学杂志,2003,9(3):184-186.
[41]林科雄,雷公藤对哮喘豚鼠GM-CSF基因转录的影响与作用机制[J],中国免疫学杂志,2000,(9):325-327.
[42]李志奎,等.雷公藤甲素对哮喘豚鼠嗜酸性粒细胞凋亡及Fas、Bcl、MRNA表达的影响[J],中国新药与临床杂志,2002,5(5):261·262.
[43]王宏长,等.中药哮喘落对哮喘大鼠肺组织白细胞介素-4、11-SMRNA 影响及相关性研究[J],广东医学,2000,21(2):107.
[44]范欣生,等.复方辛夷平喘液对哮喘豚鼠肺内ICA及淋巴细胞fas表达的影响[J],中华结核和呼吸杂志,2002,25(5):280.